2-Pyridinylmethylsulfinylbenzimidazoles
Esophagogastric Junction
Gastroesophageal Reflux
Esophageal Sphincter, Lower
The physiologic or functional barrier to GASTROESOPHAGEAL REFLUX at the esophagogastric junction. Sphincteric muscles remain tonically contracted during the resting state and form the high-pressure zone separating the lumen of the ESOPHAGUS from that of the STOMACH. (Haubrich et al, Bockus Gastroenterology, 5th ed., pp399, 415)
Proton Pump Inhibitors
Comparison of rabeprazole 20 mg versus omeprazole 20 mg in the treatment of active duodenal ulcer: a European multicentre study. (1/641)
BACKGROUND: Rabeprazole sodium is the newest member of a class of substituted benzimidazole molecules known as proton pump inhibitors. Other proton pump inhibitors have been shown to be effective in healing active duodenal ulcer. METHOD: This randomized, double-blind, multicentre study, conducted at 25 European sites, compared the efficacy and tolerability of rabeprazole and omeprazole in patients with active duodenal ulcers. One hundred and two patients with active duodenal ulcer received rabeprazole 20 mg and 103 patients omeprazole 20 mg once daily for 2 or 4 weeks, with ulcer healing monitored by endoscopy. RESULTS: After 2 weeks, complete ulcer healing was documented in 69% of patients given rabeprazole 20 mg and in 62% of patients given omeprazole 20 mg (N.S.). After 4 weeks, healing rates were 98% in the rabeprazole group and 93% in the omeprazole group (P = 0.083). Rabeprazole-treated patients had significantly greater improvement in daytime pain symptom relief than those treated with omeprazole at the conclusion of the study (P = 0.038). Both drugs were well tolerated over the 4-week treatment period. Mean changes from baseline to end-point in fasting serum gastrin were significantly greater in the rabeprazole group, but at end-point mean values were well within normal limits for both groups. No clinically meaningful changes or other between-group differences were observed in laboratory parameters. CONCLUSION: In this study, rabeprazole produced healing rates equivalent to omeprazole at weeks 2 and 4, and provided significantly greater improvement in daytime pain. Both treatments were well tolerated. (+info)Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection. (2/641)
BACKGROUND: A furazolidone-containing therapeutic regimen for Helicobacter pylori infection has attracted special interest in the face of a rising world-wide metronidazole resistant H. pylori, and the expense of currently used antimicrobial regimens. AIM: To evaluate the efficacy of furazolidone-containing regimens in eradicating H. pylori. METHODS: One-hundred and forty H. pylori positive patients with endoscopically confirmed duodenal ulcer or functional dyspepsia received one of four different regimens to eradicate H. pylori. In the first trial, the patients were randomly assigned to receive a 1-week course of furazolidone 100 mg b.d. and clarithromycin 250 mg b.d., with either tripotassium dicitrato bismuthate (TDB) 240 mg b.d. (FCB group) or lansoprazole 30 mg daily (FCL group). In the second trial, the patients were randomly assigned to receive a 1-week course of clarithromycin 250 mg b.d. and omeprazole 20 mg daily, with either furazolidone 100 mg b.d. (FCO group) or metronidazole 400 mg b.d. (MCO group). Endoscopy was repeated 4 weeks following completion of therapy with re-assessment of H. pylori status on gastric biopsies by histology and culture. RESULTS: Four patients (1 in FCB, 1 in FCO and 2 in MCO groups) dropped out because they refused a follow-up endoscopy. Eradication rates of H. pylori on an intention-to-treat basis in the FCB, FCL, FCO and MCO groups were 91% (32/35, 95% CI: 82-99%), 91% (32/35, CI: 82-99%), 86% (30/35, CI: 74-97%) and 74% (26/35, CI: 60-89%) (all P > 0.05), respectively. Mild side-effects occurred in 15% of the 140 patients. In MCO group, the eradication rate in the patients infected with metronidazole-sensitive isolates of H. pylori was 86%, but dropped to 67% in those with metronidazole-resistance strains (P = 0.198). CONCLUSION: One-week regimens containing furazolidone and clarithromycin in combination with TDB or a proton pump inhibitor fulfil the criteria for successful H. pylori therapy. (+info)Low-dose lansoprazole provides greater relief of heartburn and epigastric pain than low-dose omeprazole in patients with acid-related dyspepsia. (3/641)
AIM: To compare the relative efficacies of lansoprazole 15 mg o.m. and omeprazole 10 mg o.m. in relieving heartburn and epigastric pain in patients with acid-related dyspepsia. In addition, the study compared the safety profiles of the two treatments. METHODS: This double-blind, parallel group, randomised, multicentre study was conducted in 52 general practices in the UK. A total of 609 patients was recruited, 562 of whom were eligible for inclusion in the intention-to-treat analysis. All of the patients had experienced at least mild heartburn or mild epigastric pain persistently on at least 4 of the previous 7 days; patients with severe symptoms were excluded. 283 patients received lansoprazole 15 mg and 279 received omeprazole 10 mg, both for 4 weeks. The main efficacy measure was relief of symptoms, based on physician assessments. RESULTS: In the intention-to-treat population, a complete relief of overall primary symptoms of dyspepsia was achieved after 2 weeks in 53% of patients receiving lansoprazole and in 41% of patients receiving omeprazole (P = 0.007). After 4 weeks, 59% of the lansoprazole group and 51% of the omeprazole group had achieved complete symptom relief (P = 0. 078). Antacids were taken for additional relief of symptoms in fewer patients given lansoprazole compared to the omeprazole group in the third and fourth weeks (P = 0.035) and also significantly fewer antacids were taken by patients in the lansoprazole group compared with patients in the omeprazole group (P = 0.033). The proportion of patients reporting adverse events was similar in both groups. CONCLUSION: Low-dose lansoprazole is more effective than low-dose omeprazole in the treatment of patients with mild heartburn or epigastric pain in general practice. (+info)Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. (4/641)
AIM: To evaluate the efficacy of polaprezinc, a mucosal protective agent, in combination with a 7-day triple therapy containing lansoprazole, amoxycillin and clarithromycin, as a treatment for Helicobacter pylori. METHODS: Sixty-six consecutive patients suffering from dyspeptic symptoms with H. pylori infection were randomly allocated to one of two regimens: one group (LAC; n = 31) received lansoprazole 30 mg b.d., amoxycillin 500 mg b.d. and clarithromycin 400 mg b.d. for 7 days. The other group (LACP; n = 35) received the LAC regimen plus polaprezinc 150 mg b.d. for 7 days. H. pylori status was evaluated by rapid urease test, histology and culture at entry and 4 weeks after treatment. RESULTS: Five patients did not complete the treatment: no follow-up endoscopy was performed on two patients in the LAC group; one patient in the LAC group and two in the LACP group had their treatment stopped due to severe diarrhoea. By per protocol analysis, H. pylori eradication was achieved in 24 of the 28 evaluable patients (86%; 95% CI: 72-100%) after LAC therapy, and in 33 of the 33 evaluable patients (100%) after LACP therapy (P < 0.05). On intention-to-treat analysis, the rates of eradication were 24 of 31 patients (77%; 95% CI: 62-93%) in the LAC group, and 33 of 35 patients (94%; 95% CI: 86-100%) in the LACP group (P < 0.05). CONCLUSION: A 7-day triple therapy with lansoprazole, amoxycillin and clarithromycin is effective in H. pylori eradication, but this regimen is significantly improved by the addition of polaprezinc. (+info)The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. (5/641)
BACKGROUND: Current guidelines for Helicobacter pylori eradication recommend 7 days of a proton-pump inhibitor, clarithromycin (C), and either metronidazole (M) or amoxycillin (A). A shorter course would be cheaper and could be as effective. AIM: This study was designed to investigate the efficacy of three 5-day regimens based on lansoprazole (L). METHODS: 168 dyspepsia patients with H. pylori infection were randomized to receive a 5-day course of either LCM, LAC or CALM, and a 13C-urea breath test was performed after 4 weeks to assess eradication. RESULTS: 160 patients completed the study. Intention-to-treat eradication rates were as follows: LCM 81%, LAC 59%, CALM 88%. LCM and CALM gave significantly better eradication rates than LAC. There was no significant difference in adverse events across the three groups. Logistical regression analysis showed that the specific regimen used and the age of the patient were the only factors influencing eradication outcome. CONCLUSIONS: Five days of CALM yields acceptable eradication rates, and is cheaper than conventional 7-day proton pump inhibitor-triple therapy. It appears to offer good results in metronidazole-resistant strains of H. pylori. A randomized trial comparing 5-day CALM with conventional 7-day therapy is needed before this regimen can be recommended for routine use. (+info)The effect of antibiotic resistance on the outcome of three 1-week triple therapies against Helicobacter pylori. (6/641)
BACKGROUND: Resistance of Helicobacter pylori to antibiotics may be a major reason for treatment failure. AIM: To evaluate the effect of primary H. pylori resistance to antibiotics on the cure rates of three anti-H. pylori 1-week triple therapies. METHODS: One hundred and sixteen consecutive patients diagnosed H. pylori-positive by gastric histology, rapid urease test and culture were enrolled. Activity of tested antibiotics was determined by means of the E-test. Patients were treated for 7 days with: (i) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and metronidazole 250 mg q.d.s. (PAM); (ii) pantoprazole 40 mg o.d. plus clarithromycin 250 mg b.d. and metronidazole 250 mg q.d.s. (PCM); or (iii) pantoprazole 40 mg o.d. plus amoxycillin 1 g b.d. and clarithromycin 250 mg b.d. (PAC). Two months after completion of therapy, endoscopy and gastric biopsies were repeated. RESULTS: Primary resistance rates to metronidazole, clarithromycin and amoxycillin were 17.2, 6.9 and 0%, respectively. Overall H. pylori cure rates expressed as intention-to-treat and per protocol analyses were, respectively, 79% and 86% with PAM, 82% and 89% with PCM, and 85% and 85% with PAC. Significantly lower cure rates were observed in metronidazole-resistant patients treated with PAM (56% vs. 96%, P = 0.01) or PCM (50% vs. 97%, P = 0.01). A trend towards lower H. pylori cure rates was observed in clarithromycin-resistant patients treated with PCM (67% vs. 91%, P = 0.74) or PAC (50% vs. 87%, P = 0.68). CONCLUSION: Primary resistance to metronidazole influences the H. pylori cure rate of anti-H. pylori proton pump inhibitor-based triple therapies which include this antibiotic. A similar trend exists for primary clarithromycin resistance. (+info)Treatment of H. pylori infection: the reality. (7/641)
Despite the wide dissemination of information on Helicobacter pylori, there is still a great deal of variation in how general practitioners treat the infection and in which circumstances they prescribe eradication therapy for H. pylori. Specialty societies have developed consensus guidelines that recommend a strategy to test and treat dyspeptic patients for H. pylori infection although the data to support these recommendations are weak at the present time. As a result, there is still confusion about the indications for treatment and the treatment regimens that are likely to be effective in routine clinical practice. (+info)The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprazole or ranitidine. (8/641)
BACKGROUND: The antisecretory effect of omeprazole on intragastric pH is decreased in the absence of Helicobacter pylori. AIM: To investigate the effect of H. pylori eradication on intragastric pH during lansoprazole or ranitidine dosing in 41 asymptomatic H. pylori-positive subjects. METHOD: Two groups of healthy H. pylori-positive volunteers were investigated. One group was dosed with lansoprazole 30 mg at 08.00 hours for at least 8 days, before and after 2 weeks of placebo-controlled double-blind eradication therapy using ranitidine bismuth citrate 400 mg b.d. and clarithromycin 500 mg b.d. The other group was dosed with ranitidine 300 mg at 23.00 hours for at least 8 days using the same trial design. An upper endoscopy was performed to establish H. pylori status by rapid urease test, culture and histology before both periods of dosing. Twenty-four hour intragastric pH recording was performed on the final day of all periods of dosing. RESULTS: H. pylori eradication significantly decreased the intragastric pH reached during lansoprazole treatment throughout all periods of the day. Intragastric pH during ranitidine treatment was not affected by H. pylori eradication, except for the late-night period. CONCLUSION: H. pylori eradication has a more pronounced effect on the acid-inhibiting properties of lansoprazole than on those of ranitidine. (+info)
Compare Glyco-Flex Classic 600 mg vs. Glyco-Flex I for Dogs | 1-800-PetMeds®
The Proton-Pump Inhibitor Lansoprazole Enhances Amyloid Beta Production
Lansoprazole Medication Classification - Harga Lansoprazole 1 Box
Lansoprazole 30 Mg Obat Untuk Apa - Can You Buy Lansoprazole Over The Counter Uk
Obese Children Require Lower Doses of Pantoprazole Than Nonobese Peers by Valentina Shakhnovich, P Brian Smith et al.
DailyMed - PANTOPRAZOLE SODIUM tablet, delayed release
Negative Inotropy of the Gastric Proton Pump Inhibitor Pantoprazole in Myocardium From Humans and Rabbits | Circulation
DailyMed - PANTOPRAZOLE SODIUM - pantoprazole sodium tablet, delayed release
Pantoprazole Injection - Zuche Pharmaceuticals
Acheter Pilule Pantoprazole 40Mg En Ligne Bon Marche Rapide - A - Blog View - Egypt Youth Network
Buy Lansoprazole Online
Buy Pantaloc 40 mg (Pantoprazole) Online at Lowest Price
Rabeprazole + mosapride : usage, side effects, expert advice and rabeprazole + mosapride based medicines | 1mg
Import Data And Price Of Rabeprazole For Injection | www.eximpulse.com
NDC 0781-3232 Pantoprazole Sodium Pantoprazole Sodium
Pantoprazole Sodium Injection
Pantoprazole, What is Pantoprazole? About its Science, Chemistry and Structure
Rabeprazole EC by Sorres - Uses, Side Effects, Interactions - MedBroadcast.com
NDC 55111-739 Lansoprazole Lansoprazole
lansoprazole vidal juventus
A comparative prospective study to assess the clinical efficacy and safety of pantoprazole monotherapy versus pantoprazole and...
Up in Smoke? Uncovering a Lack of Evidence for Proton Pump Inhibitors as a Source of THC Immunoassay False Positives - AACC.org
What Is Aciphex Rabeprazole Sodium 20 Mg For - Rabeprazole Sodium Buy Online
Rabeprazole 20 Mg - Topics - MedsChat
Pantoprazole and liver enzymes
Buy Pantoprazole Online
how can i stop that burning feeling in my chest and nose from reflux ive tryed gaviscon. and tumms and are on lansoprazole ...
Having discomfort, bloating and uneasiness in stomach. On rabeprazole. What could be the reason?
Sodium Rabeprazole CHOS - Drugs.com
Rabeprazole Sodium Api Manufacturers,Manufacturer -Enaldrugs
Rabeprazole Liconsa - Drugs.com
Rabeprazole Forums - MedsChat
Pantoprazole for Injection by Teva - Pharmasave
Pantoprazole by Riva - Pharmasave
Pantoprazole Coupon - Save 75% with our Coupons - January 2018
Lansoprazole | Prescriptions Online | PostMyMeds Ltd
Rabeprazole - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction | Drug Index | Pediatric Oncall
Proton-Pump Inhibitors Category Listing & Drugs List on Catalog.md. From Lanzogastro to Novoprazol, page 3.
Pharmaceutical composition combining tenatoprazole and an anti-inflammatory agent - Sidem Pharma
PZ 40 mg - (Pantoprazole Sodium Sesquihydrate) Tablet | Price, Usage, Dosage, and Brand Substitutes with similar Generic ...
Lansoprazole For Injection - Chengdu Baiyu Pharmaceutical Co.,Ltd - ecplaza.net
Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive...
Hol lehet megvásárolni Aciphex tabletta eladó Vásárlás Magyarországra | Rabeprazole Sodium 10/20mg.
Aciphex (Rabeprazole Sodium) - Where To Order Cheapest Aciphex in Dallas | Tenacious C Forums
Global Rabeprazole Sodium Market 2020 Growth Drivers - JSN Chemicals, Zhejiang Yongtai Technology, Shanghai Pharma Group...
Rabeprazole 10Mg Pas Cher Site Fiable. Vente De Aciphex Sans Ordonnance En France - GGWAdvice
Buy Aciban (Pantoprazole) Online
Købe Gastrointestinal - Cool pan (Brand name: protonix) Pantoprazole uden recept
Protonix pantoprazole sodium - High Quality Pills !.
Lansoprazole Generic Price Philippines - Lansoprazole Vs Omeprazole Cost
Manfaat Lancid Lansoprazole - Harga Prazotec Lansoprazole 30 Mg
Oral sulfasalazine as a clinical BCRP probe substrate: Pharmacokinetic effects of genetic variation (C421A) and pantoprazole...
Proton pump inhibitor Forum
Lansoprazole - LiverTox - NCBI Bookshelf
Get PDF - Proton pump inhibitors therapy and the risk of pneumonia: a systematic review and meta-analysis of randomized...
Social Network - Blog View - Farmacia Online Donde Comprar Lansoprazole 30Mg Fiable Estados
Proton pump inhibitor - encyclopedia article - Citizendium
New Research Links Proton Pump Inhibitors and Kidney Damage | Lopez McHugh LLP
Frontiers | The Influence of Proton Pump Inhibitors on the Fecal Microbiome of Infants with Gastroesophageal Reflux-A...
Viagra kaufen hamburg
Use of tenatoprazole for the treatment of gastroesophageal reflux disease - Schutze, Francois
Rabeprazole Sodium Tablets | Rabeprazole Sodium 20Mg | Aciphex 20Mg
First lansoprazole infant
Determination of the Dexlansoprazole in Bulk and Spiked Human Plasma by Extraction Spectrophotometry
Plus it
Study of the improvement effect of proton pump inhibitors on symptoms in patients with reflux esophagitis (RE): a randomized...
Buy Rabeprazole And Itopride Capsules | Wholesaler, Supplier, Distributors, Exporters At Tissuepharma.com
Lansoprazole by Pro Doc - Uses, Side Effects, Interactions - MedBroadcast.com
Buy Lansoprazole Online
Buy Lansoprazole Online
Pantoprazole stomach ulcer - Doctors answer your questions
Rabeprazole 20 mg. Tablets - Rabeprazole 20 mg. Tablets Exporter, Manufacturer, Distributor, Supplier, Trading Company,...
Pantoprazole Injection Manufacturer,Pantoprazole Injection Supplier,Exporter
PCD PHARMA FRANCHISE IN PANTOPRAZOLE 40 MG INJECTION - PCD PHARMA FRANCHISE IN PANTOPRAZOLE 40 MG INJECTION Manufacturer,...
Will you have Hyperglycemia with Lansoprazole - from FDA reports - eHealthMe
Lansoprazole CAS 103577-45-3 Antiulcer Pharmaceutical API Powder - Passionchemical
Plus it
Plus it
Treatments for GERD: Proton Pump Inhibitors
Buy Lansox (Lansoprazole) Online
Proton Pump Inhibitors (PPIs) | Custom Essays Writers
Meta-analysis links proton pump inhibitors to kidney disease
DMOZ - Health: Pharmacy: Drugs and Medications: P: Pantoprazole
How Important Are Proton Pump Inhibitors for Intensive Care Patients? | gutsandgrowth
Toxicity of long-term use of proton pump inhibitors in children | Archives of Disease in Childhood
Alternatives to Proton Pump Inhibitors | LIVESTRONG.COM
Cureus | The Safety of Long-term Daily Usage of a Proton Pump Inhibitor: A Literature Review
Proton Pump Inhibitor Lawsuits
Zurcal for Symptomatic gastro esophageal reflux disease and For long term management and prevention of relapse
Proton Pump Inhibitors Linked With Increased Risk of Contracting COVID-19 | Everyday Health
Dexilant is a medication drug that is classified as a proton pump inhibitor.
Is Your Proton Pump Inhibitor Causing More Harm Than Good? - NutriChem
Proton Pump Inhibitors | Reston Hospital Center
Pittsburgh Proton Pump Inhibitors Lawsuits | Robert Peirce & Associates, P.C.
Proton pump inhibitor use not linked to increased risk of Alzheimers disease
Alaina Pharma- Levosulpride and Rabeprazole Capsule |GERD- Third Party Manufacturers
2-Pyridinylmethylsulfinylbenzimidazoles | Profiles RNS
Compounds that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. Several of the compounds in this ... "2-Pyridinylmethylsulfinylbenzimidazoles" is a descriptor in the National Library of Medicines controlled vocabulary thesaurus ... This graph shows the total number of publications written about "2-Pyridinylmethylsulfinylbenzimidazoles" by people in this ... Below are the most recent publications written about "2-Pyridinylmethylsulfinylbenzimidazoles" by people in Profiles. ...
Pantoprazole decreases gastroesophageal muscle tone in newborn rats via rho-kinase inhibition
Christopher Welsh 1 , Moshe Yair Kasirer 2 , Jingyi Pan 1 , Yulia Shifrin 1 , Jaques Belik 3 ... 2 Department of Paediatrics, University of Toronto, Toronto, Ontario, Canada; and.. *3 Physiology & Experimental Medicine ... strongly suggesting that it is a ROCK-2 inhibitor. To the extent that these findings can be extrapolated to human neonates, the ... we evaluated the tissue ROCK-2 and CPI-17 activity. Pantoprazole reduced myosin light chain phosphatase MYPT-1, but not CPI-17 ...
Tolperisone | Harvard Catalyst Profiles | Harvard Catalyst
MeSH Browser
Aminopyridines | Colorado PROFILES
Hospital Administration - Arthur H. Aufses, Jr., MD Archives at Mount Sinai
Picolines | Profiles RNS
Carbolines | Profiles RNS
Bisbenzimidazole | Profiles RNS
Dimethindene | Profiles RNS
Tolperisone | Profiles RNS
Long-term management of GERD in the elderly with pantoprazole
The prevalence of gastroesophageal reflux disease (GERD) increases with age and elderly are more likely to develop severe disease. Older patients often complain of less severe or frequent heartburn than younger patients and they may present with atypical symptoms such as dysphagia, weight loss, or e …
Decreased Activity and Genetic Polymorphisms of CYP2C19 in Behçet's Disease - PubMed
Mustafa Tugrul Goktas 1 2 , Ragip Ozgur Karaca 1 , Said Kalkisim 1 , Lokman Cevik 1 , Levent Kilic 3 , Ali Akdogan 3 , Melih O ... Mustafa Tugrul Goktas 1 2 , Ragip Ozgur Karaca 1 , Said Kalkisim 1 , Lokman Cevik 1 , Levent Kilic 3 , Ali Akdogan 3 , Melih O ... 2007 Feb;46(2):153-6. doi: 10.1111/j.1365-4632.2007.02957.x. Int J Dermatol. 2007. PMID: 17269966 ... 2015 Oct;71(10):1223-8. doi: 10.1007/s00228-015-1899-7. Epub 2015 Aug 2. Eur J Clin Pharmacol. 2015. PMID: 26233334 ...
Fatal toxic epidermal necrolysis due to lansoprazole - PubMed
Toxic epidermal necrolysis (TEN) is a serious cutaneous reaction and is most commonly drug induced. It is associated with significant morbidity and mortality. We describe a patient who developed fatal TEN after re-exposure to lansoprazole. Three years previously he presented with erythema multiforme …
MeSH Browser
2-Pyridinylmethylsulfinylbenzimidazoles [D02.886.640.074] * Lansoprazole [D02.886.640.074.249] * Omeprazole [D02.886.640.074. ... 2-Pyridinylmethylsulfinylbenzimidazoles [D03.383.725.024] * Lansoprazole [D03.383.725.024.249] * Omeprazole [D03.383.725.024. ... 2-Pyridinylmethylsulfinylbenzimidazoles [D03.633.100.103.034] * Lansoprazole [D03.633.100.103.034.249] * Omeprazole [D03.633. ... 2-Methylpyridine 2-Benzimidazole Sulfoxides Term UI T670169. Date03/30/2006. LexicalTag NON. ThesaurusID NLM (2007). ...
MeSH Browser
2-Pyridinylmethylsulfinylbenzimidazoles [D02.886.640.074] * Lansoprazole [D02.886.640.074.249] * Omeprazole [D02.886.640.074. ... 2-Pyridinylmethylsulfinylbenzimidazoles [D03.383.725.024] * Lansoprazole [D03.383.725.024.249] * Omeprazole [D03.383.725.024. ... 2-Pyridinylmethylsulfinylbenzimidazoles [D03.633.100.103.034] * Lansoprazole [D03.633.100.103.034.249] * Omeprazole [D03.633. ... 2-Methylpyridine 2-Benzimidazole Sulfoxides Term UI T670169. Date03/30/2006. LexicalTag NON. ThesaurusID NLM (2007). ...
MeSH Browser
sg:pub.10.1007/s10620-005-2907-z - Springer Nature SciGraph
The mean 2-week posttreatment ulcer size value by rabeprazole did not significantly differ among the different CYP2C19 ... The mean 2-week posttreatment ulcer size value by rabeprazole did not significantly differ among the different CYP2C19 ... The mean 2-week posttreatment ulcer size value by rabeprazole did not significantly differ among the different CYP2C19 ... The endoscopic evaluation was performed at the baseline and 2- and 8-week posttreatment periods. The endoscopic improvement of ...
NDF-RT Code NDF-RT Name
2,3,4,5-Tetrahydro-8-chloro-3-methyl-5-phenyl-1H-3-benzazepin-7-ol N0000166927 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3- ... quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy- N0000175328 beta 2-Glycoprotein I N0000169400 beta ... 2-Ethyl 2-(4-Nitrophenyl) Ester N0000167283 Dibenz(b,f)(1,4)oxazepine-10(11H)-carboxylic acid, 8-chloro-, 2-acetylhydrazide ... Member 2 N0000180288 Nuclear Receptor Subfamily 1, Group F, Member 3 N0000180205 Nuclear Receptor Subfamily 2, Group C, Member ...
NEW (2007) MESH HEADINGS WITH SCOPE NOTES (UNIT RECORD FORMAT; 09/07/2006
There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2). HN - 2007 ... 2-Pyridinylmethylsulfinylbenzimidazoles UI - D053799 MN - D2.886.640.74 MN - D3.383.725.24 MN - D3.438.103.34 MS - Compounds ... that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. Several of the compounds in this class are ...
DeCS
4-(5-(4-Methyl-1-piperazinyl)(2,5-bi-1H-benzimidazol)-2-yl)phenol, trihydrochloride Bisbenzimide ... 4-(5-(4-Methyl-1-piperazinyl)(2,5-bi-1H-benzimidazol)-2-yl)phenol, trihydrochloride. Bisbenzimidazole Trihydrochloride. ... 4-(5-(5-(4-Methylpiperazin-1-yl)benzimidazol-2- yl)benzimidazol-2-yl)phenol ...
Alexander Burnett's research topics | Profiles RNS
Concept scores are derived automatically based on a persons publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicines controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a persons concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months. ...
Picolinic Acids | Profiles RNS
Thienopyridines | Profiles RNS
Carbolines | Profiles RNS
Benomyl | Profiles RNS
Students - Arthur H. Aufses, Jr., MD Archives at Mount Sinai
Profiles RNS Covid Authors
Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS ... An integrated drug repurposing strategy for the rapid identification of potential SARS-CoV-2 viral inhibitors. Sci Rep. 2020 08 ... Inhibitors of VPS34 and fatty-acid metabolism suppress SARS-CoV-2 replication. Cell Rep. 2021 08 03; 36(5):109479. ... Implications for therapeutic strategies against SARS-CoV-2. Cell Calcium. 2021 03; 94:102360. ...
TERM
2),MePhe(4),Met(0)-ol-enkephalin D-Alanine Transaminase D-Amino-Acid Oxidase D-Aspartate Oxidase D-Aspartic Acid D-Xylulose ... 25-Hydroxyvitamin D 2 25-Hydroxyvitamin D3 1-alpha-Hydroxylase 2H-Benzo(a)quinolizin-2-ol, 2-Ethyl-1,3,4,6,7,11b-hexahydro-3- ... bcl-2 Homologous Antagonist-Killer Protein bcl-2-Associated X Protein Bcl-2-Like Protein 11 bcl-Associated Death Protein bcl-X ... Member 2 ATP Binding Cassette Transporter, Sub-Family G, Member 5 ATP Binding Cassette Transporter, Sub-Family G, Member 8 ATP ...
MeSH1
- 2-Pyridinylmethylsulfinylbenzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings) . (jefferson.edu)
Heterocyclic Compounds1
- Heterocyclic compounds that contain 4H,5H,6H,7H-thieno[2,3-c]pyridine as part of their structure. (uams.edu)
CYP2C192
- The genotyping for CYP2C19 *2, *3 and *17 polymorphisms was made using PCR-RFLP. (nih.gov)
- The mean 2-week posttreatment ulcer size value by rabeprazole did not significantly differ among the different CYP2C19 genotypes, whereas the mean value in the homozygous extensive metabolizer patients treated with omeprazole was significantly (P = 0.0057) greater than in those with rabeprazole. (springernature.com)
Therapeutic1
- Lysosomal ion channels involved in cellular entry and uncoating of enveloped viruses: Implications for therapeutic strategies against SARS-CoV-2. (covidauthors.org)
PYRIDINE1
- Compounds with general formula C5H4N(CO2H) derived from PYRIDINE, having a carboxylic acid substituent at the 2-position. (ouhsc.edu)
Compounds2
- Compounds that contain benzimidazole joined to a 2-methylpyridine via a sulfoxide linkage. (nih.gov)
- Multidisciplinary Approaches Identify Compounds that Bind to Human ACE2 or SARS-CoV-2 Spike Protein as Candidates to Block SARS-CoV-2-ACE2 Receptor Interactions. (covidauthors.org)